| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 57 |
| 1 | CARBOPLATIN | 55 |
| 2 | FUROSEMIDE | 36 |
| 3 | BEVACIZUMAB | 35 |
| 4 | CYCLOPHOSPHAMIDE | 35 |
| 5 | CYCLOPHOSPHAMIDE FOR INJECTION | 35 |
| 6 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 35 |
| 7 | NIVOLUMAB | 34 |
| 8 | CISPLATIN | 32 |
| 9 | METHOTREXATE SODIUM | 31 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IBRITUMOMAB TIUXETAN | 6 | 0.0039 |
| 1 | GADOPICLENOL | 1 | 0.0036 |
| 2 | ESTAZOLAM | 7 | 0.0035 |
| 3 | PHENOBARBITAL SODIUM | 1 | 0.0024 |
| 4 | ISRADIPINE | 1 | 0.0018 |
| 5 | SEVELAMER HYDROCHLORIDE | 1 | 0.0017 |
| 6 | SILODOSIN | 7 | 0.0017 |
| 7 | BARICITINIB | 5 | 0.0016 |
| 8 | DINUTUXIMAB | 1 | 0.0012 |
| 9 | SMOFLIPID | 1 | 0.0011 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 106 | 0.0011 |
| 1 | Prostacycline [EPC] | 1 | 0.0011 |
| 2 | Thyroid Stimulating Hormone [EPC] | 1 | 0.0010 |
| 3 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 1 | 0.0009 |
| 4 | CD38-directed Cytolytic Antibody [EPC] | 5 | 0.0009 |
| 5 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 6 | Live Attenuated Bacillus Calmette-Guerin Immunotherapy [EPC] | 1 | 0.0006 |
| 7 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 3 | 0.0005 |
| 8 | Programmed Death Ligand-1 Blocker [EPC] | 9 | 0.0004 |
| 9 | Lipid Emulsion [EPC] | 1 | 0.0004 |